GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Asset Turnover

Burzynski Research Institute (Burzynski Research Institute) Asset Turnover : 0.00 (As of Feb. 2024)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Burzynski Research Institute's Revenue for the three months ended in Feb. 2024 was $0.00 Mil. Burzynski Research Institute's Total Assets for the quarter that ended in Feb. 2024 was $0.00 Mil. Therefore, Burzynski Research Institute's Asset Turnover for the quarter that ended in Feb. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Burzynski Research Institute's annualized ROE % for the quarter that ended in Feb. 2024 was 4,840.00%. It is also linked to ROA % through Du Pont Formula. Burzynski Research Institute's annualized ROA % for the quarter that ended in Feb. 2024 was -96,800.00%.


Burzynski Research Institute Asset Turnover Historical Data

The historical data trend for Burzynski Research Institute's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute Asset Turnover Chart

Burzynski Research Institute Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Burzynski Research Institute Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Burzynski Research Institute's Asset Turnover

For the Biotechnology subindustry, Burzynski Research Institute's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burzynski Research Institute's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's Asset Turnover falls into.



Burzynski Research Institute Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Burzynski Research Institute's Asset Turnover for the fiscal year that ended in Feb. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Feb. 2024 )/( (Total Assets (A: Feb. 2023 )+Total Assets (A: Feb. 2024 ))/ count )
=0/( (0.002+0.002)/ 2 )
=0/0.002
=0.00

Burzynski Research Institute's Asset Turnover for the quarter that ended in Feb. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=0/( (0.001+0.002)/ 2 )
=0/0.0015
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Burzynski Research Institute  (OTCPK:BZYR) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Burzynski Research Institute's annulized ROE % for the quarter that ended in Feb. 2024 is

ROE %**(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-1.452/-0.03
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.452 / 0)*(0 / 0.0015)*(0.0015/ -0.03)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.05
=ROA %*Equity Multiplier
=-96,800.00 %*-0.05
=4,840.00 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Burzynski Research Institute's annulized ROA % for the quarter that ended in Feb. 2024 is

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=-1.452/0.0015
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.452 / 0)*(0 / 0.0015)
=Net Margin %*Asset Turnover
= %*0
=-96,800.00 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Burzynski Research Institute Asset Turnover Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute (Burzynski Research Institute) Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute (Burzynski Research Institute) Headlines

No Headlines